Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy

SIMPLE SUMMARY: Regorafenib and TAS-102 showed a survival benefit against placebo, and both drugs are approved for the treatment of metastatic colorectal cancer (mCRC) beyond second-line. The highly differential toxicity profile of both substances has led to a potentially biased perception of drug t...

Descripción completa

Detalles Bibliográficos
Autores principales: Huemer, Florian, Piringer, Gudrun, Schlintl, Verena, Hackl, Hubert, Rinnerthaler, Gabriel, Thaler, Josef, Greil, Richard, Weiss, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599669/
https://www.ncbi.nlm.nih.gov/pubmed/33007814
http://dx.doi.org/10.3390/cancers12102812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599669/
https://www.ncbi.nlm.nih.gov/pubmed/33007814
http://dx.doi.org/10.3390/cancers12102812

Ejemplares similares